PMDA drug package insert

フェスゴ配合皮下注 MA

PMDA Prescription drug · 中外製薬株式会社 · package insert Nov 22, 2023

Key facts

Brand names フェスゴ配合皮下注 MA, フェスゴ配合皮下注 IN
Nonproprietary names ペルツズマブ(遺伝子組換え)・トラスツズマブ(遺伝子組換え)・ボルヒアルロニダーゼ アルファ(遺伝子組換え)
Companies 製造販売元/中外製薬株式会社
Product type Prescription drug
Therapeutic category 抗悪性腫瘍剤; 抗HER2ヒト化モノクローナル抗体・ヒアルロン酸分解酵素配合剤 HER2:Human Epidermal Growth Factor Receptor Type 2(ヒト上皮増殖因子受容体2型、別称:c-erbB-2)
Therapeutic category codes 874291
YJ codes 4291501A1028, 4291501A2024
Approval numbers 30500AMX00268, 30500AMX00269
Package insert edition 第2版
Package insert date Nov 22, 2023
PMDA document key 450045_4291501A1028_1
PMDA company code 450045

At a glance

  • 1–9 Package insert revisions
  • 10–99 Related PMDA documents
  • None Safety communications
  • Yes PMDA review report published
  • Yes Risk management plan (RMP)

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMDA approved drugs and package inserts (Japan)

Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.

Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date:

Browse all PMDA approved drugs and package inserts (Japan)